. 2020 Jun 1;5(22):12583–12595. doi: 10.1021/acsomega.0c01592

Table 1. Advantages of Nanocarriers in the Treatment of Neurodegenerative Disease³⁰⁻³⁴.

type of nanocarrier used for clinical trial	size range (nm)	neurodegenerative disease	drug	applications and advantages
polymeric nanoparticle	1–100	Alzheimer’s disease	MEM-PEG-PLGA-NPs	reduction of β-amyloid plaques, disruption of β-amyloid (Aβ) aggregates
polymeric nanoparticle	1–100	Parkinson’s disease	PLGA-NPs	reach lysosomes and restore their impaired function
liposome	50–450	Huntington’s disease	apolipoprotein E (ApoE) amino acid	increase cellular drug uptake as a versatile “nanovehicle” to deliver drug across the BBB
dendrimers	1.5–10	Alzheimer’s disease	KLVFF peptides	prevent Aβ-induced spatial memory impairments
carbon nanotubes (CNTs)	1–100	stroke	aggregated single-walled CNTs	ability to repair damaged neural tissue
micelles	10–100	Alzheimer’s disease	resveratrol-loaded polymeric micelles	protect cells against Aβ-induced oxidative stress and apoptosis

Table 1. Advantages of Nanocarriers in the Treatment of Neurodegenerative Disease30−34.